CD8+ T cell-independent tumor regression induced by Fc-OX40L and therapeutic vaccination in a mouse model of glioma

Journal of Immunology

Volumn 192, Issue 1, 2014, Pages 224-233

  Murphy, Katherine A ^a   Erickson, Jami R ^a   Johnson, Charles S ^b   Seiler, Charles E ^c   Bedi, Jessica ^a   Hu, Peisheng ^d   Pluhar, G Elizabeth ^c   Epstein, Alan L ^d   Ohlfest, John R ^a,c  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FC OX40 LIGAND; TUMOR VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; CANCER IMMUNIZATION; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; GLIOMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME; T CELL DEPLETION; TUMOR REGRESSION;

EID: 84891070447     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1301633     Document Type: Article

References (39)

1. Nelson, D. J., S. Mukherjee, C. Bundell, S. Fisher, D. van Hagen, and B. Robinson. 2001. Tumor progression despite efficient tumor antigen crosspresentation and effective "arming" of tumor antigen-specific CTL. J. Immunol. 166: 5557-5566.
2. Wang, R. F. 2001. The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. Trends Immunol. 22: 269-276.
3. Heimberger, A. B., and J. H. Sampson. 2011. Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma? Neuro-oncol. 13: 3-13.
4. Lee, K. H., E. Wang, M. B. Nielsen, J. Wunderlich, S. Migueles, M. Connors, S. M. Steinberg, S. A. Rosenberg, and F. M. Marincola. 1999. Increased vaccinespecific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J. Immunol. 163: 6292-6300.
5. Hung, K., R. Hayashi, A. Lafond-Walker, C. Lowenstein, D. Pardoll, and H. Levitsky. 1998. The central role of CD4(+) T cells in the antitumor immune response. J. Exp. Med. 188: 2357-2368.
6. Perez-Diez, A., N. T. Joncker, K. Choi, W. F. Chan, C. C. Anderson, O. Lantz, and P. Matzinger. 2007. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 109: 5346-5354.
7. Hirschhorn-Cymerman, D., S. Budhu, S. Kitano, C. Liu, F. Zhao, H. Zhong, A. M. Lesokhin, F. Avogadri-Connors, J. Yuan, Y. Li, et al. 2012. Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype. J. Exp. Med. 209: 2113-2126.
8. Muranski, P., Z. A. Borman, S. P. Kerkar, C. A. Klebanoff, Y. Ji, L. Sanchez-Perez, M. Sukumar, R. N. Reger, Z. Yu, S. J. Kern, et al. 2011. Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity 35: 972-985.
9. Braumüller, H., T. Wieder, E. Brenner, S. Aßmann, M. Hahn, M. Alkhaled, K. Schilbach, F. Essmann, M. Kneilling, C. Griessinger, et al. 2013. T-helper-1-cell cytokines drive cancer into senescence. Nature 494: 361-365.
10. Mucida, D., M. M. Husain, S. Muroi, F. van Wijk, R. Shinnakasu, Y. Naoe, B. S. Reis, Y. Huang, F. Lambolez, M. Docherty, et al. 2013. Transcriptional reprogramming of mature CD4+ helper T cells generates distinct MHC class IIrestricted cytotoxic T lymphocytes. Nat. Immunol. 14: 281-289.
11. Curran, M. A., T. L. Geiger, W. Montalvo, M. Kim, S. L. Reiner, A. Al-Shamkhani, J. C. Sun, and J. P. Allison. 2013. Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin. J. Exp. Med. 210: 743-755.
12. Soghoian, D. Z., and H. Streeck. 2010. Cytolytic CD4(+) T cells in viral immunity. Expert Rev. Vaccines 9: 1453-1463.
13. Crawford, A., M. Macleod, T. Schumacher, L. Corlett, and D. Gray. 2006. Primary T cell expansion and differentiation in vivo requires antigen presentation by B cells. J. Immunol. 176: 3498-3506.
14. Deeken, J. F., and W. Löscher. 2007. The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin. Cancer Res. 13: 1663-1674.
15. Pallasch, C. P., A. K. Struss, A. Munnia, J. König, W. I. Steudel, U. Fischer, and E. Meese. 2005. Autoantibodies against GLEA2 and PHF3 in glioblastoma: tumor-associated autoantibodies correlated with prolonged survival. Int. J. Cancer 117: 456-459.
16. Beatty, G. L., E. G. Chiorean, M. P. Fishman, B. Saboury, U. R. Teitelbaum, W. Sun, R. D. Huhn, W. Song, D. Li, L. L. Sharp, et al. 2011. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331: 1612-1616.
17. Tepper, R. I., R. L. Coffman, and P. Leder. 1992. An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science 257: 548-551.
18. Purwar, R., C. Schlapbach, S. Xiao, H. S. Kang, W. Elyaman, X. Jiang, A. M. Jetten, S. J. Khoury, R. C. Fuhlbrigge, V. K. Kuchroo, et al. 2012. Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells. Nat. Med. 18: 1248-1253.
19. Liu, R. B., B. Engels, A. Arina, K. Schreiber, E. Hyjek, A. Schietinger, D. C. Binder, E. Butz, T. Krausz, D. A. Rowley, et al. 2012. Densely granulated murine NK cells eradicate large solid tumors. Cancer Res. 72: 1964-1974.
20. Harling-Berg, C. J., T. J. Park, and P. M. Knopf. 1999. Role of the cervical lymphatics in the Th2-type hierarchy of CNS immune regulation. J. Neuroimmunol. 101: 111-127.
21. Gordon, L. B., S. C. Nolan, H. F. Cserr, P. M. Knopf, and C. J. Harling-Berg. 1997. Growth of P511 mastocytoma cells in BALB/c mouse brain elicits CTL response without tumor elimination: a new tumor model for regional central nervous system immunity. J. Immunol. 159: 2399-2408.
22. Hodi, F. S., S. J. O'Day, D. F. McDermott, R. W. Weber, J. A. Sosman, J. B. Haanen, R. Gonzalez, C. Robert, D. Schadendorf, J. C. Hassel, et al. 2010. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363: 711-723.
23. Topalian, S. L., F. S. Hodi, J. R. Brahmer, S. N. Gettinger, D. C. Smith, D. F. McDermott, J. D. Powderly, R. D. Carvajal, J. A. Sosman, M. B. Atkins, et al. 2012. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366: 2443-2454.
24. Pardee, A. D., A. K. Wesa, and W. J. Storkus. 2009. Integrating costimulatory agonists to optimize immune-based cancer therapies. Immunotherapy 1: 249-264.
25. Murphy, K. A., M. G. Lechner, F. E. Popescu, J. Bedi, S. A. Decker, P. Hu, J. R. Erickson, M. G. O'Sullivan, L. Swier, A. M. Salazar, et al. 2012. An in vivo immunotherapy screen of costimulatory molecules identifies Fc-OX40L as a potent reagent for the treatment of established murine gliomas. Clin. Cancer Res. 18: 4657-4668.
26. Wu, A., S. Oh, S. Gharagozlou, R. N. Vedi, K. Ericson, W. C. Low, W. Chen, and J. R. Ohlfest. 2007. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma. J. Immunother. 30: 789-797.
27. Waisman, A., M. Kraus, J. Seagal, S. Ghosh, D. Melamed, J. Song, Y. Sasaki, S. Classen, C. Lutz, F. Brombacher, et al. 2007. IgG1 B cell receptor signaling is inhibited by CD22 and promotes the development of B cells whose survival is less dependent on Ig alpha/beta. J. Exp. Med. 204: 747-758.
28. Waisman, A., A. L. Croxford, and F. Demircik. 2008. New tools to study the role of B cells in cytomegalovirus infections. Med. Microbiol. Immunol. 197: 145-149.
29. Sadun, R. E., W. E. Hsu, N. Zhang, Y. C. Nien, S. A. Bergfeld, H. Sabzevari, M. E. Lutsiak, L. Khawli, P. Hu, and A. L. Epstein. 2008. Fc-mOX40L fusion protein produces complete remission and enhanced survival in 2 murine tumor models. J. Immunother. 31: 235-245.
30. Ruby, C. E., M. A. Yates, D. Hirschhorn-Cymerman, P. Chlebeck, J. D. Wolchok, A. N. Houghton, H. Offner, and A. D. Weinberg. 2009. Cutting edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right. J. Immunol. 183: 4853-4857.
31. Burocchi, A., P. Pittoni, A. Gorzanelli, M. P. Colombo, and S. Piconese. 2011. Intratumor OX40 stimulation inhibits IRF1 expression and IL-10 production by Treg cells while enhancing CD40L expression by effector memory T cells. Eur. J. Immunol. 41: 3615-3626.
32. Challacombe, J. M., A. Suhrbier, P. G. Parsons, B. Jones, P. Hampson, D. Kavanagh, G. E. Rainger, M. Morris, J. M. Lord, T. T. Le, et al. 2006. Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate. J. Immunol. 177: 8123-8132.
33. Delves, P. J., and I. M. Roitt. 2000. The immune system: second of two parts. N. Engl. J. Med. 343: 108-117.
34. Brady, M. S., F. Lee, H. Petrie, D. D. Eckels, and J. S. Lee. 2000. CD4(+) T cells kill HLA-class-II-antigen-positive melanoma cells presenting peptide in vitro. Cancer Immunol. Immunother. 48: 621-626.
35. Trandem, K., J. Zhao, E. Fleming, and S. Perlman. 2011. Highly activated cytotoxic CD8 T cells express protective IL-10 at the peak of coronavirus-induced encephalitis. J. Immunol. 186: 3642-3652.
36. Palmer, E. M., B. C. Holbrook, S. Arimilli, G. D. Parks, and M. A. Alexander-Miller. 2010. IFNgamma-producing, virus-specific CD8+ effector cells acquire the ability to produce IL-10 as a result of entry into the infected lung environment. Virology 404: 225-230.
37. Liu, C., Y. Lou, G. Lizée, H. Qin, S. Liu, B. Rabinovich, G. J. Kim, Y. H. Wang, Y. Ye, A. G. Sikora, et al. 2008. Plasmacytoid dendritic cells induce NK celldependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J. Clin. Invest. 118: 1165-1175.
38. Zaini, J., S. Andarini, M. Tahara, Y. Saijo, N. Ishii, K. Kawakami, M. Taniguchi, K. Sugamura, T. Nukiwa, and T. Kikuchi. 2007. OX40 ligand expressed by DCs costimulates NKT and CD4+ Th cell antitumor immunity in mice. J. Clin. Invest. 117: 3330-3338.
39. Baumann, R., S. Yousefi, D. Simon, S. Russmann, C. Mueller, and H. U. Simon. 2004. Functional expression of CD134 by neutrophils. Eur. J. Immunol. 34: 2268-2275.